AGO2 in T-prolymphocytic leukemia (T-PLL)
A new editorial paper titled "AGO2 in T-prolymphocytic leukemia: its canonical and noncanonical deregulation and function" has been published in Oncotarget.
Aug 7, 2023
0
2
A new editorial paper titled "AGO2 in T-prolymphocytic leukemia: its canonical and noncanonical deregulation and function" has been published in Oncotarget.
Aug 7, 2023
0
2
McMaster researchers have uncovered a fast and effective way to detect cancer stem cells before the disease recurs in adults who previously underwent treatment.
Jul 17, 2023
0
39
A new editorial paper titled "Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability" has been published in Oncotarget.
Jun 28, 2023
0
2
Tiny packets of molecular cargo shed by cancer cells seed the foundations for metastasis at distant sites in the body.
Jun 19, 2023
0
35
Treatment with luspatercept improved red blood cell counts and erythroid responses compared to treatment with epoetin alfa in patients with myelodysplastic syndromes (MDS), allowing the majority to no longer require regular ...
May 25, 2023
0
3
New animal research is helping explain why at least five people have become HIV-free after receiving a stem cell transplant. The study's insights may bring scientists closer to developing what they hope will become a widespread ...
May 25, 2023
1
29
Chronic myeloid leukemia (CML) is a type of blood cancer that arises from malignant changes in blood-forming cells of the bone marrow. It mainly occurs in older individuals and represents about 20% of all adult leukemia cases.
May 16, 2023
0
5
Chemotherapy has been the most effective treatment to date for young and fit patients with chronic lymphocytic leukemia (CLL). The disease is the most common form of leukemia in the Western world, causing a substantial health ...
May 10, 2023
0
43
A new clinical tool developed by a team of researchers led by the Dana-Farber Cancer Institute pinpoints which Clonal hematopoiesis patients are at highest risk for cancer progression. Their work was published this week in ...
Apr 26, 2023
0
2
Immunotherapy with blinatumomab leads to a strongly improved survival rate—from 66% to 93%—for children with an aggressive form of acute lymphoblastic leukemia (ALL). They also had fewer side effects from the treatment. ...
Apr 26, 2023
0
51